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A carbapenem-resistant Acinetobacter baumannii clinical isolate belonging to European clone II and sequence type 2 was recov-
ered from a patient in the Son Espases hospital in Mallorca, Spain. Genetic analysis showed the presence of the blaOXA-23 gene in
association with the widely disseminated transposon Tn2006. This is the first reported identification of A. baumannii carrying
blaOXA-23 in Spain.
A
cinetobacter baumannii is responsible for hospital outbreaks,
and it is considered one of the most important nosocomial
pathogens causing bacteremia, pneumonia, and other respira-
tory and urinary tract infections (1, 2). The abilities to acquire
resistance mechanisms and to persist in the environment for
long periods of time make this pathogen difficult to eradicate
from the clinical setting (3, 4). The resistance of A. baumannii
isolates to carbapenems is on the rise mainly in association with
a variety of combined mechanisms, among which the produc-
tion of acquired carbapenem-hydrolyzing OXA-type class D
b-lactamases (CHDLs), OXA-23 in particular, has been iden-
tified worldwide (2).
Here we report the first case of OXA-23 in an A. baumannii
clinical isolate in Spain and in association with the widely spread
Tn2006 transposon.
OXA-23 was identified in a clinical isolate from a 59-year-old
male patient admitted to the Department of Pneumology at the
Son Espases hospital inMallorca, Spain, in February 2010 because
of increased dyspnea, coughing, chills, and purulent secretions
during the previous 3 days. The patient was born in Portugal and
had lived in Palma de Mallorca since 1998, although he had trav-
eled to Portugal and France during the previous year. The patient
had been hospitalized in Lisbon between 7 and 23 December 2009
and then again in another hospital between 26 December 2009
and 8 January 2010. He was a former smoker and had needed
multiple hospital admissions because of exacerbations of chronic
obstructive pulmonary disease. His regular medication included
bronchodilators but no antibiotics. On the second day after ad-
mission, A. baumannii was isolated from his sputum and the pa-
tient was empirically treated with levofloxacin (500 to 750 mg/
day) but switched to intravenous colistin (2 to 3 MU/8 h) after 6
days because of susceptibility test results. The patient improved
and was discharged for specialized home care. After the initial
isolation, periodic sputum cultures were taken for several months
with no further isolation of the strain.
A. baumannii isolate AB 308 was initially identified by Mi-
croScan and confirmed by matrix-assisted laser desorption ion-
ization–time of flight mass spectrometry (Bruker Daltonics
GmbH, Leipzig, Germany). Antibiotic susceptibilities were deter-
mined by MicroScan (Siemens) for most antimicrobial agents,
except colistin and tigecycline, which were determined by Etest
(AB bioMérieux, Solna, Sweden). These results were interpreted
according to CLSI guidelines (5). The AB 308 isolate was resistant
to amikacin (.256 mg/ml), ceftazidime (.128 mg/ml), tetracy-
cline, ciprofloxacin, gentamicin, netilmicin (.64 mg/ml), pipera-
cillin (.512 mg/ml), imipenem, and meropenem (.16 mg/ml).
The MIC of both tigecycline and colistin was 0.5 mg/ml.
PCR detection of metallo-beta-lactamase and CHDL genes
(6–8) was only positive for blaOXA-51 and blaOXA-23. The insertion
sequence ISAba1was found upstream of blaOXA-23 but not up-
stream of blaOXA-51.
The genetic location of blaOXA-23 was determined by S1 nu-
clease pulsed-field gel electrophoresis (PFGE) and Southern blot
analysis with a digoxigenin-labeled probe (Roche, Barcelona,
Spain) matching the blaOXA-23 gene. S1 PFGE revealed a band of
ca. 100 kb with no signal hybridization with the probe. However,
we detected a positive signal matching the bacterial chromosome
indicating the chromosomal location of blaOXA-23 (Fig. 1).
Characterization of the genetic structures surrounding the
blaOXA-23 gene was performed by inverse PCR (9) with primers
OXA23invF (5=-GGAAAGACTGGTTGGGCAATGG-3=) and
OXA-23invR (5=-CACCTCAGGTGTGCTGGTTATTC-3=) and
revealed genetic structures neighboring the blaOXA-23 gene consis-
tent with the arrangement of the previously described composite
transposon Tn2006 (10, 11).
AB 308 was included within European clone II (EC-II) (12),
and multilocus sequence typing performed according to the
scheme devised by Nemec et al. (13) allowed the allocation of the
AB 308 strain to sequence type 2 (ST2) (http://www.pasteur.fr
/recherche/genopole/PF8/mlst/Abaumannii.html).
In this report, we describe the first identification of an A. bau-
mannii clinical isolate carrying blaOXA-23 associated with Tn2006
in Spain. Until recently, A. baumannii isolates bearing CHDLs in
Spain were related mainly to OXA-24 (14, 15). Interestingly, the
emergence and spread of several outbreak or sporadic A. bauman-
nii strains producing OXA-23 related to EC-II and ST2 have been
reported around the world (4, 11, 16–18).
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Moreover, in countries in the Mediterranean region, there
seems to be a trend toward the replacement of OXA-58/OXA-24-
producing A. baumannii by OXA-23 producers, also associated
with A. baumannii strains belonging to EC-II and ST2 and carry-
ing Tn2006. In central Italy, an interesting replacement of
blaOXA-58 with blaOXA-23 belonging to EC-II has recently been es-
tablished (18, 19) and a similar abrupt shift has also been reported
in Greece and Algeria, where 72.4% and 92% of the carbapenem-
resistant isolates tested harbored the blaOXA-23 gene (20, 21), while
the blaOXA-58 gene was predominant in those countries half a de-
cade ago. All of the blaOXA-23 genes from Italy and Greece were
located within Tn2006 transposons, either chromosomally or in
plasmids.
In Portugal, carbapenem-resistant A. baumannii isolates have
typically been associated with OXA-24 but a predominance of
blaOXA-23 (63%) has been detected since 2006. All of the isolates
belonged to EC-II and ST2 and carried Tn2006 chromosomally
(17). While the replacement of OXA-58 by OXA-23 might be ex-
plained by the selective advantage associated with the higher car-
bapenemase activity of OXA-23, the selective advantage of
OXA-23 over OXA-24 producers is not clear but could be linked
to additional features within the carrying clone (i.e., extensive
multidrug resistance), which might explain why OXA-23 in Italy
andGreece is associatedwith epidemiologically diverse clones car-
rying either chromosomal or plasmidic blaOXA-23, while in Portu-
gal, OXA-23 dissemination is caused by a particular clone (17).
The AB 308 strain described in this study, however, was not
related to any outbreak in Spain and represented the only OXA-
23-producing A. baumannii strain out of 456 Acinetobacter strains
collected in a nationwide multicenter study in Spain performed
during 2010. Therefore, it is not likely that OXA-23 producers
were disseminating throughout Spain in 2010 and AB 308 was
probably acquired during a recent trip to either France or Portu-
gal.Nevertheless, recent investigations have reported twoOXA-23
outbreaks in Spain in 2012 (J. Vila and G. Bou, personal commu-
nication); therefore, in the years to come, we might expect an
eruption of A. baumannii strains carrying OXA-23 in this country
as well.
The genomic plasticity of the strains carrying blaOXA-23 associ-
ated with the composite transposon Tn2006 allows mobilization
or transposition events to occur more easily, since insertions can
occur in different locations on the chromosome or even in plas-
mids, and the emerging spread of carbapenem-resistant A. bau-
mannii strains associated with transposon structures and the
worldwide dissemination of EC-II and ST2 represent a worrying
threat, as well as an important challenge for surveillance and in-
fection control measures.
ACKNOWLEDGMENTS
This study was supported by the Spanish Ministry of Health (FIS PI10/
00056) and by the Instituto de Salud Carlos III-FEDER, Spanish Network
for theResearch in InfectiousDiseases (REIPI RD06/0008). Thisworkwas
also supported by funding from the European Community (TROCAR
contract HEALTH-F3-2008-223031). M. Tomás was financially sup-
ported by the Miguel Servet Program (CHU a Coruña and ISCIII).
REFERENCES
1. Antunes LC, Imperi F, Carattoli A, Visca P. 2011. Deciphering the
multifactorial nature ofAcinetobacter baumanniipathogenicity. PLoSOne
6:e22674. doi:10.1371/journal.pone.0022674.
2. Roca I, Espinal P, Vila-Farres X, Vila J. 2012. The Acinetobacter bau-
mannii oxymoron: commensal hospital dweller turned pan-drug-
resistant menace. Front. Microbiol. 3:148.
3. Espinal P, Marti S, Vila J. 2012. Effect of biofilm formation on the
survival of Acinetobacter baumannii on dry surfaces. J. Hosp. Infect. 80:
56–60.
4. Kohlenberg A, Brummer S, Higgins PG, Sohr D, Piening BC, de Grahl
C, Halle E, Ruden H, Seifert H. 2009. Outbreak of carbapenem-resistant
Acinetobacter baumannii carrying the carbapenemase OXA-23 in a Ger-
man university medical centre. J. Med. Microbiol. 58:1499–1507.
5. CLSI. 2011. Performance standards for antimicrobial susceptibility test-
ing, 15th informational supplement, M100-515. Clinical and Laboratory
Standards Institute, Wayne, PA.
6. Ellington MJ, Kistler J, Livermore DM, Woodford N. 2007. Multiplex
PCR for rapid detection of genes encoding acquired metallo-beta-
lactamases. J. Antimicrob. Chemother. 59:321–322.
7. Poirel L, Walsh TR, Cuvillier V, Nordmann P. 2011. Multiplex PCR for
detection of acquired carbapenemase genes. Diagn.Microbiol. Infect. Dis.
70:119–123.
8. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S,
Amyes SG, Livermore DM. 2006. Multiplex PCR for genes encoding
prevalent OXA carbapenemases in Acinetobacter spp. Int. J. Antimicrob.
Agents 27:351–353.
9. Espinal P, Fugazza G, López Y, Kasma M, Lerman Y, Malhotra-Kumar
S, Goossens H, Carmeli Y, Vila J. 2011. Dissemination of an NDM-2-
producing Acinetobacter baumannii clone in an Israeli rehabilitation cen-
ter. Antimicrob. Agents Chemother. 55:5396–5398.
10. Corvec S, Poirel L, Naas T, Drugeon H, Nordmann P. 2007. Genetics
and expression of the carbapenem-hydrolyzing oxacillinase gene
blaOXA-23 in Acinetobacter baumannii. Antimicrob. Agents Chemother.
51:1530–1533.
11. Mugnier PD, Poirel L, Naas T, Nordmann P. 2010. Worldwide dissem-
ination of the blaOXA-23 carbapenemase gene of Acinetobacter baumannii.
Emerg. Infect. Dis. 16:35–40.
12. Turton JF, Gabriel SN, Valderrey C, Kaufmann ME, Pitt TL. 2007. Use
of sequence-based typing andmultiplex PCR to identify clonal lineages of
outbreak strains of Acinetobacter baumannii. Clin. Microbiol. Infect. 13:
807–815.
FIG 1 Southern blot assay. Lane a, PFGE analysis of the AB 308 strain by
digestion with S1 nuclease. Lane b, hybridization with a blaOXA-23 probe. The
black arrow indicates the chromosomal location with positive hybridization
with the blaOXA-23 probe. The white arrow indicates a plasmid band with no
hybridization with the probe. Lanes M, lambda ladder PFGE marker (New
England BioLabs).
Espinal et al.
590 aac.asm.org Antimicrobial Agents and Chemotherapy
 o
n
 J
u
n
e
 1
0
, 2
0
1
4
 b
y
 g
u
e
s
t
h
ttp
://a
a
c
.a
s
m
.o
rg
/
D
o
w
n
lo
a
d
e
d
 fro
m
 
13. Nemec A, Krizova L, Maixnerova M, Diancourt L, van der Reijden TJ,
Brisse S, van den Broek P, Dijkshoorn L. 2008. Emergence of carbap-
enem resistance in Acinetobacter baumannii in the Czech Republic is as-
sociated with the spread of multidrug-resistant strains of European clone
II. J. Antimicrob. Chemother. 62:484–489.
14. Bou G, Oliver A, Martinez-Beltrán J. 2000. OXA-24, a novel class D
beta-lactamase with carbapenemase activity in an Acinetobacter bauman-
nii clinical strain. Antimicrob. Agents Chemother. 44:1556–1561.
15. Ruiz M, Marti S, Fernandez-Cuenca F, Pascual A, Vila J. 2007. High
prevalence of carbapenem-hydrolysing oxacillinases in epidemiologically
related and unrelated Acinetobacter baumannii clinical isolates in Spain.
Clin. Microbiol. Infect. 13:1192–1198.
16. Grosso F, Carvalho KR, Quinteira S, Ramos A, Carvalho-Assef AP, Asensi
MD, Peixe L. 2011. OXA-23-producing Acinetobacter baumannii: a new hot-
spot of diversity in Rio de Janeiro? J. Antimicrob. Chemother. 66:62–65.
17. Grosso F, Quinteira S, Peixe L. 2011. Understanding the dynamics of
imipenem-resistant Acinetobacter baumannii lineages within Portugal.
Clin. Microbiol. Infect. 17:1275–1279.
18. Minandri F, D’Arezzo S, Antunes LC, Pourcel C, Principe L,
Petrosillo N, Visca P. 2012. Evidence of diversity among epidemio-
logically related carbapenemase-producing Acinetobacter baumannii
strains belonging to international clonal lineage II. J. Clin. Microbiol.
50:590–597.
19. D’Arezzo S, Principe L, Capone A, Petrosillo N, Petrucca A, Visca P.
2011. Changing carbapenemase gene pattern in an epidemic multidrug-
resistant Acinetobacter baumannii lineage causing multiple outbreaks in
central Italy. J. Antimicrob. Chemother. 66:54–61.
20. Liakopoulos A, Miriagou V, Katsifas EA, Karagouni AD, Daikos GL,
Tzouvelekis LS, Petinaki E. 2012. Identification of OXA-23-producing
Acinetobacter baumannii in Greece, 2010 to 2011. Euro Surveill. 17(11):
20117.
21. Touati M, Diene SM, Racherache A, Dekhil M, Djahoudi A, Rolain
JM. 2012. Emergence of blaOXA-23 and blaOXA-58 carbapenemase-
encoding genes in multidrug-resistant Acinetobacter baumannii iso-
lates from University Hospital of Annaba, Algeria. Int. J. Antimicrob.
Agents 40:89 –91.
OXA-23-Producing A. baumannii from Spain
January 2013 Volume 57 Number 1 aac.asm.org 591
 o
n
 J
u
n
e
 1
0
, 2
0
1
4
 b
y
 g
u
e
s
t
h
ttp
://a
a
c
.a
s
m
.o
rg
/
D
o
w
n
lo
a
d
e
d
 fro
m
 
